Pharmacological or genetic activation of HO-1 significantly improves survival of many tumors, such as hepatomas, thyroid carcinomas, chronic myeloid leukemias, gastric carcinomas, and gliomas. This evidence concerns the gene HMOX1 and chronic myelogenous leukemia, BCR-ABL1 positive.